MONISTAT 7 (miconazole nitrate) by Design Pharmaceuticals is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1982.
Drug data last refreshed 1h ago
MONISTAT 7 is a vaginal suppository formulation of miconazole nitrate, a fungicidal azole antifungal indicated for vulvovaginal candidiasis and related fungal infections. The drug works by inhibiting fungal cytochrome P-450-mediated lanosterol demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity. It is administered intravaginally with minimal systemic absorption (<1% urinary/fecal recovery).
Product approaching loss of exclusivity with moderate competitive pressure (30%) signals transition from growth to defensive marketing and cost management focus.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT 7 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job openings reflect the product's mature, LOE-approaching stage with minimal hiring activity. Roles on this team focus on defensive brand strategies, market share protection, and generic transition planning rather than growth initiatives.